HCWB

S-1/A - HCW Biologics Inc. (0001828673) (Filer)

S-1 - HCW Biologics Inc. (0001828673) (Filer)

PRE 14A - HCW Biologics Inc. (0001828673) (Filer)

8-K - HCW Biologics Inc. (0001828673) (Filer)

10-K - HCW Biologics Inc. (0001828673) (Filer)

8-K - HCW Biologics Inc. (0001828673) (Filer)

MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, today reported financial results and recent business highlights for its three months ended December 31, 2025. On November 17, 2025, the Company initiated its first-in-human clinical trial to evaluate HCW9302, the lead product candidate for the Company's program to develop treatments for autoimmune disorders and proinflammatory diseases, in patients with areata alopecia. HCW9302 is a subcutaneously injectable, first-i

8-K - HCW Biologics Inc. (0001828673) (Filer)

 Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in the form of a transferable equity interest in licensee Initiation of Phase 1 clinical study in China by licensee expected in the first half of 2027 HCW Biologics has "free" option to reclaim the rights to the Americas territory MIRAMAR, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company") (NASDAQ:HCWB), a U.S.-based commercial- and clinical-stage biopharmaceutical company focused on supporting or developing novel fusion immunotherapies to treat autoimmune diseases, cancer, and senescence-associated dysplasia, announced the receipt of ful

Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells manufactured using HCW9206 showed strong anti-tumor activity in leukemia and enhanced antiviral potency in HIV suggesting potential for curative outcomes Employing HCW9206 as a manufacturing reagent may lower the cost of CAR-T manufacturing MIRAMAR, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB" or the "Company") (NASDAQ:HCWB), is a U.S.-based commercial- and clinical-stage biopharmaceutical company focused on supporting or developing novel immunotherapies to treat autoimmune d

DEF 14A - HCW Biologics Inc. (0001828673) (Filer)

PRE 14A - HCW Biologics Inc. (0001828673) (Filer)

8-K - HCW Biologics Inc. (0001828673) (Filer)

MIRAMAR, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and disease, today reported that, on February 26, 2026, the Nasdaq Hearings Panel (the "Panel") of The Nasdaq Stock Market LLC ("Nasdaq" or the "Exchange") found that the Company regained compliance with all continued listing rules of The Nasdaq Capital Market.  Dr. Hing C. Wong, the Company's Founder and CEO, stated "We appreciate the discretion of the Nasdaq Panel to provide us with the time we needed t

The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar

8-K - HCW Biologics Inc. (0001828673) (Filer)

424B4 - HCW Biologics Inc. (0001828673) (Filer)

EFFECT - HCW Biologics Inc. (0001828673) (Filer)

MIRAMAR, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend health span by targeting the link between chronic inflammation and disease, today announced the pricing of its follow-on offering of an aggregate of 2,477,292 units at a purchase price of $0.6055 per unit priced at-the-market under Nasdaq rules. Each unit consists of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant, each to purchase one share of common stock. The warrant will have an exercise price of $0.6055 per share, will be exer

SCHEDULE 13G - HCW Biologics Inc. (0001828673) (Subject)

S-1/A - HCW Biologics Inc. (0001828673) (Filer)

S-1/A - HCW Biologics Inc. (0001828673) (Filer)

8-K - HCW Biologics Inc. (0001828673) (Filer)

HCW Biologics receiving cash fee and co-founder shares in Trimmunevalued at $7.0 million Trimmune will hold exclusive worldwide license for rights to high potential preclinical molecule created with HCW Biologics' TRBC drug development platform Initiation of Phase 1 clinical study expected in the first half of 2027 HCW Biologics retains royalty-free option to reclaim the rights to the Americas territory MIRAMAR, Fla., Feb. 13, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCW Biologics") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend health span by targeting the link between chronic inflamm

S-1 - HCW Biologics Inc. (0001828673) (Filer)